These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19162492)

  • 1. GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies.
    Hasler F; Kuznetsova OF; Krasikova RN; Cservenyak T; Quednow BB; Vollenweider FX; Ametamey SM; Westera G
    Appl Radiat Isot; 2009 Apr; 67(4):598-601. PubMed ID: 19162492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of [(18)F]altanserin bolus injection PET data. II: consideration of radiolabeled metabolites in humans.
    Price JC; Lopresti BJ; Meltzer CC; Smith GS; Mason NS; Huang Y; Holt DP; Gunn RN; Mathis CA
    Synapse; 2001 Jul; 41(1):11-21. PubMed ID: 11354009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography.
    Quednow BB; Treyer V; Hasler F; Dörig N; Wyss MT; Burger C; Rentsch KM; Westera G; Schubiger PA; Buck A; Vollenweider FX
    Neuroimage; 2012 Feb; 59(4):3922-32. PubMed ID: 21996132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No-carrier-added nucleophilic 18F-labelling in an electrochemical cell exemplified by the routine production of [18F]altanserin.
    Hamacher K; Coenen HH
    Appl Radiat Isot; 2006 Sep; 64(9):989-94. PubMed ID: 16829074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach.
    Pinborg LH; Adams KH; Svarer C; Holm S; Hasselbalch SG; Haugbøl S; Madsen J; Knudsen GM
    J Cereb Blood Flow Metab; 2003 Aug; 23(8):985-96. PubMed ID: 12902843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation and quantification of [18F]altanserin binding in the rat brain using blood input and reference tissue modeling.
    Riss PJ; Hong YT; Williamson D; Caprioli D; Sitnikov S; Ferrari V; Sawiak SJ; Baron JC; Dalley JW; Fryer TD; Aigbirhio FI
    J Cereb Blood Flow Metab; 2011 Dec; 31(12):2334-42. PubMed ID: 21750562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct comparison of [(18) F]MH.MZ and [(18) F] altanserin for 5-HT2A receptor imaging with PET.
    Hansen HD; Ettrup A; Herth MM; Dyssegaard A; Ratner C; Gillings N; Knudsen GM
    Synapse; 2013 Jun; 67(6):328-37. PubMed ID: 23390031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analyses of [(18)F] altanserin bolus injection PET data. I: consideration of radiolabeled metabolites in baboons.
    Price JC; Lopresti BJ; Mason NS; Holt DP; Huang Y; Mathis CA
    Synapse; 2001 Jul; 41(1):1-10. PubMed ID: 11354008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats.
    Lemaire C; Cantineau R; Guillaume M; Plenevaux A; Christiaens L
    J Nucl Med; 1991 Dec; 32(12):2266-72. PubMed ID: 1744713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Test-retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain.
    Smith GS; Price JC; Lopresti BJ; Huang Y; Simpson N; Holt D; Mason NS; Meltzer CC; Sweet RA; Nichols T; Sashin D; Mathis CA
    Synapse; 1998 Dec; 30(4):380-92. PubMed ID: 9826230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-efficient and convenient synthesis of [(18)F]altanserin for human PET imaging by a new work-up procedure.
    Massarweh G; Kovacevic M; Rosa-Neto P; Evans AC; Diksic M; Schirrmacher R
    Appl Radiat Isot; 2009 Nov; 67(11):2040-3. PubMed ID: 19692252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls.
    Sadzot B; Lemaire C; Maquet P; Salmon E; Plenevaux A; Degueldre C; Hermanne JP; Guillaume M; Cantineau R; Comar D
    J Cereb Blood Flow Metab; 1995 Sep; 15(5):787-97. PubMed ID: 7673371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A complete remote-control system for reliable preparation of [18F]altanserin.
    Tan PZ; Baldwin RM; Soufer R; Garg PK; Charney DS; Innis RB
    Appl Radiat Isot; 1999 May; 50(5):923-7. PubMed ID: 10214711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent.
    Tan PZ; Baldwin RM; Van Dyck CH; Al-Tikriti M; Roth B; Khan N; Charney DS; Innis RB
    Nucl Med Biol; 1999 Aug; 26(6):601-8. PubMed ID: 10587097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved synthesis and metabolic stability analysis of the dopamine transporter ligand [(18)F]FECT.
    Chitneni SK; Garreau L; Cleynhens B; Evens N; Bex M; Vermaelen P; Chalon S; Busson R; Guilloteau D; Van Laere K; Verbruggen A; Bormans G
    Nucl Med Biol; 2008 Jan; 35(1):75-82. PubMed ID: 18158946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin.
    van Dyck CH; Tan PZ; Baldwin RM; Amici LA; Garg PK; Ng CK; Soufer R; Charney DS; Innis RB
    J Nucl Med; 2000 Feb; 41(2):234-41. PubMed ID: 10688105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm.
    van Dyck CH; Soares JC; Tan PZ; Staley JK; Baldwin RM; Amici LA; Fu X; Garg PK; Seibyl JP; Charney DS; Innis RB
    Nucl Med Biol; 2000 Nov; 27(8):715-22. PubMed ID: 11150702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [¹⁸F]Altanserin and small animal PET: impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT₂A receptor densities in the rat brain.
    Kroll T; Elmenhorst D; Matusch A; Celik AA; Wedekind F; Weisshaupt A; Beer S; Bauer A
    Nucl Med Biol; 2014 Jan; 41(1):1-9. PubMed ID: 24120220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suitability of [18F]altanserin and PET to determine 5-HT2A receptor availability in the rat brain: in vivo and in vitro validation of invasive and non-invasive kinetic models.
    Kroll T; Elmenhorst D; Matusch A; Wedekind F; Weisshaupt A; Beer S; Bauer A
    Mol Imaging Biol; 2013 Aug; 15(4):456-67. PubMed ID: 23456885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of the alpha4beta2* nicotinic acetylcholine receptor ligand 2-[(18)F]Fluoro-A-85380 and its metabolites in human blood during PET investigation: a methodological study.
    Sorger D; Becker GA; Patt M; Schildan A; Grossmann U; Schliebs R; Seese A; Kendziorra K; Kluge M; Brust P; Mukhin AG; Sabri O
    Nucl Med Biol; 2007 Apr; 34(3):331-42. PubMed ID: 17383583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.